Mesoblast Reports Financial Results and Operational Update for the Fiscal Year Ended June 30, 2024

Potential initial product approval and preparation for commercial launch

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular therapeutics for inflammatory diseases, today provided an operational update and reported financial results for the period ended June 30, 2024.

Silviu Itescu, Chief Executive of Mesoblast, said: “Over the past year, we have built significant momentum in our interactions with the US Food and Drug Administration (FDA) for each of our Phase 3 products.